Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7789 in Relapsed or Refractory Classical Hodgkin Lymphoma
2022-502773-41-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of sabestomig in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events (AEs), immune-mediated AEs (imAEs), and serious AEs (SAEs) - Part A dose escalation, Incidence of AEs leading to discontinuation of sabestomig - Part A dose escalation and 7 more. Started Feb 2024; status: completed.
02
Drugs
sabestomig
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-502773-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502773-41-00.